Literature DB >> 25035100

TERT promoter mutations and BRAF mutations are rare in sporadic, and TERT promoter mutations are absent in NF1-related malignant peripheral nerve sheath tumors.

Hendrikus J Dubbink1, Hannah Bakels, Edward Post, Ellen C Zwarthoff, Robert M Verdijk.   

Abstract

Hot spot mutations in the promoter region of telomerase reverse transcriptase (TERT promoter mutations) occur frequently in tumors of neuroectodermal origin such as melanoma and glioma. Many of these tumors are of neuroectodermal or ectomesenchymal origin which is suggestive of TERT promoter mutations playing a role in the development of malignant peripheral nerve sheath tumors (MPNSTs). In melanoma a correlation has been suggested between the occurrence of TERT promoter mutations and v-RAF murine sarcoma viral oncogene homolog B1 (BRAF) mutations. We investigated TERT promoter and BRAF mutation frequency in respectively 94 and 86 consecutive MPNST cases from our institute. TERT promoter mutation analysis on DNA from formalin-fixed, paraffin-embedded specimens was performed by SNaPshot analysis. Sequence analysis of BRAF was performed by bidirectional DNA sequencing. We identified TERT C228T or C250T promoter mutations in 10 % (9/94) and BRAF V600E mutations in 3 % (3/86) of MPNSTs. All TERT promoter- and BRAF mutations occurred in NF1 unrelated tumors. One co-occurrence of a TERT promoter- and a BRAF mutation was observed. In comparison with other neuroectodermal derived malignant neoplasms, TERT promoter mutations occur at relatively low frequency in MPNSTs. The observation of TERT promotor and BRAF mutations in sporadic MPNSTs and the absence of TERT promotor and rarity of BRAF mutations in NF1 related tumors may imply an alternative genetic route of tumor progression in both patient groups.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25035100     DOI: 10.1007/s11060-014-1553-8

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  24 in total

1.  Inhibition of mutated, activated BRAF in metastatic melanoma.

Authors:  Keith T Flaherty; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Peter J O'Dwyer; Richard J Lee; Joseph F Grippo; Keith Nolop; Paul B Chapman
Journal:  N Engl J Med       Date:  2010-08-26       Impact factor: 91.245

2.  Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system.

Authors:  Christian Koelsche; Felix Sahm; David Capper; David Reuss; Dominik Sturm; David T W Jones; Marcel Kool; Paul A Northcott; Benedikt Wiestler; Katja Böhmer; Jochen Meyer; Christian Mawrin; Christian Hartmann; Michel Mittelbronn; Michael Platten; Benjamin Brokinkel; Marcel Seiz; Christel Herold-Mende; Andreas Unterberg; Jens Schittenhelm; Michael Weller; Stefan Pfister; Wolfgang Wick; Andrey Korshunov; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2013-10-24       Impact factor: 17.088

3.  Schwann cell precursors from nerve innervation are a cellular origin of melanocytes in skin.

Authors:  Igor Adameyko; Francois Lallemend; Jorge B Aquino; Jorge A Pereira; Piotr Topilko; Thomas Müller; Nicolas Fritz; Anna Beljajeva; Makoto Mochii; Isabel Liste; Dmitry Usoskin; Ueli Suter; Carmen Birchmeier; Patrik Ernfors
Journal:  Cell       Date:  2009-10-16       Impact factor: 41.582

4.  Telomerase activity is a biomarker for high grade malignant peripheral nerve sheath tumors in neurofibromatosis type 1 individuals.

Authors:  Kiran K Mantripragada; Matthew Caley; Phil Stephens; Christopher J Jones; Lan Kluwe; Abhijit Guha; Victor Mautner; Meena Upadhyaya
Journal:  Genes Chromosomes Cancer       Date:  2008-03       Impact factor: 5.006

5.  A prospective 10 year follow up study of patients with neurofibromatosis type 1.

Authors:  M H Cnossen; A de Goede-Bolder; K M van den Broek; C M Waasdorp; A P Oranje; H Stroink; H J Simonsz; A M van den Ouweland; D J Halley; M F Niermeijer
Journal:  Arch Dis Child       Date:  1998-05       Impact factor: 3.791

6.  Clonal BRAF mutations in melanocytic nevi and initiating role of BRAF in melanocytic neoplasia.

Authors:  Iwei Yeh; Andreas von Deimling; Boris C Bastian
Journal:  J Natl Cancer Inst       Date:  2013-05-20       Impact factor: 13.506

7.  BRAF V600E and KRAS G12S mutations in peripheral nerve sheath tumours.

Authors:  César Serrano; Sara Simonetti; Javier Hernández-Losa; Claudia Valverde; Cristina Carrato; Silvia Bagué; Ruth Orellana; Rosa Somoza; Teresa Moliné; Joan Carles; Pere Huguet; Cleofé Romagosa; Santiago Ramón y Cajal
Journal:  Histopathology       Date:  2012-11-27       Impact factor: 5.087

8.  COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer.

Authors:  Simon A Forbes; Nidhi Bindal; Sally Bamford; Charlotte Cole; Chai Yin Kok; David Beare; Mingming Jia; Rebecca Shepherd; Kenric Leung; Andrew Menzies; Jon W Teague; Peter J Campbell; Michael R Stratton; P Andrew Futreal
Journal:  Nucleic Acids Res       Date:  2010-10-15       Impact factor: 16.971

9.  TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma.

Authors:  Marc Remke; Vijay Ramaswamy; John Peacock; David J H Shih; Christian Koelsche; Paul A Northcott; Nadia Hill; Florence M G Cavalli; Marcel Kool; Xin Wang; Stephen C Mack; Mark Barszczyk; A Sorana Morrissy; Xiaochong Wu; Sameer Agnihotri; Betty Luu; David T W Jones; Livia Garzia; Adrian M Dubuc; Nataliya Zhukova; Robert Vanner; Johan M Kros; Pim J French; Erwin G Van Meir; Rajeev Vibhakar; Karel Zitterbart; Jennifer A Chan; László Bognár; Almos Klekner; Boleslaw Lach; Shin Jung; Ali G Saad; Linda M Liau; Steffen Albrecht; Massimo Zollo; Michael K Cooper; Reid C Thompson; Oliver O Delattre; Franck Bourdeaut; François F Doz; Miklós Garami; Peter Hauser; Carlos G Carlotti; Timothy E Van Meter; Luca Massimi; Daniel Fults; Scott L Pomeroy; Toshiro Kumabe; Young Shin Ra; Jeffrey R Leonard; Samer K Elbabaa; Jaume Mora; Joshua B Rubin; Yoon-Jae Cho; Roger E McLendon; Darell D Bigner; Charles G Eberhart; Maryam Fouladi; Robert J Wechsler-Reya; Claudia C Faria; Sidney E Croul; Annie Huang; Eric Bouffet; Cynthia E Hawkins; Peter B Dirks; William A Weiss; Ulrich Schüller; Ian F Pollack; Stefan Rutkowski; David Meyronet; Anne Jouvet; Michelle Fèvre-Montange; Nada Jabado; Marta Perek-Polnik; Wieslawa A Grajkowska; Seung-Ki Kim; James T Rutka; David Malkin; Uri Tabori; Stefan M Pfister; Andrey Korshunov; Andreas von Deimling; Michael D Taylor
Journal:  Acta Neuropathol       Date:  2013-10-31       Impact factor: 17.088

10.  TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities.

Authors:  Christian Koelsche; Marcus Renner; Wolfgang Hartmann; Regine Brandt; Burkhard Lehner; Nina Waldburger; Ingo Alldinger; Thomas Schmitt; Gerlinde Egerer; Roland Penzel; Eva Wardelmann; Peter Schirmacher; Andreas von Deimling; Gunhild Mechtersheimer
Journal:  J Exp Clin Cancer Res       Date:  2014-04-11
View more
  8 in total

1.  Sox10--a marker for not only schwannian and melanocytic neoplasms but also myoepithelial cell tumors of soft tissue: a systematic analysis of 5134 tumors.

Authors:  Markku Miettinen; Peter A McCue; Maarit Sarlomo-Rikala; Wojciech Biernat; Piotr Czapiewski; Janusz Kopczynski; Lester D Thompson; Jerzy Lasota; Zengfeng Wang; John F Fetsch
Journal:  Am J Surg Pathol       Date:  2015-06       Impact factor: 6.394

Review 2.  The role of the immune system in neurofibromatosis type 1-associated nervous system tumors.

Authors:  Souvik Karmakar; Karlyne M Reilly
Journal:  CNS Oncol       Date:  2016-12-21

3.  TERT promoter mutations are rare in bone and soft tissue sarcomas of Japanese patients.

Authors:  Tsuyoshi Saito; Keisuke Akaike; Aiko Kurisaki-Arakawa; Midori Toda-Ishii; Kenta Mukaihara; Yoshiyuki Suehara; Tatsuya Takagi; Kazuo Kaneko; Takashi Yao
Journal:  Mol Clin Oncol       Date:  2015-11-09

4.  Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors.

Authors:  Azadeh Amirnasr; Rob M Verdijk; Patricia F van Kuijk; Walter Taal; Stefan Sleijfer; Erik A C Wiemer
Journal:  PLoS One       Date:  2017-08-15       Impact factor: 3.240

Review 5.  Telomere maintenance in soft tissue sarcomas.

Authors:  Nicholas Eastley; Barbara Ottolini; Carmen Garrido; Jacqueline A Shaw; Thomas Alasdair McCulloch; Robert U Ashford; Nicola J Royle
Journal:  J Clin Pathol       Date:  2017-02-09       Impact factor: 3.411

6.  Telomere erosion in NF1 tumorigenesis.

Authors:  Rhiannon E Jones; Julia W Grimstead; Ashni Sedani; Duncan Baird; Meena Upadhyaya
Journal:  Oncotarget       Date:  2017-06-20

7.  Establishment and genomic characterization of a sporadic malignant peripheral nerve sheath tumor cell line.

Authors:  Jody Fromm Longo; Stephanie N Brosius; Iya Znoyko; Victoria A Alers; Dorea P Jenkins; Robert C Wilson; Andrew J Carroll; Daynna J Wolff; Kevin A Roth; Steven L Carroll
Journal:  Sci Rep       Date:  2021-03-11       Impact factor: 4.996

Review 8.  Telomere Maintenance Mechanisms in Cancer.

Authors:  Tiago Bordeira Gaspar; Ana Sá; José Manuel Lopes; Manuel Sobrinho-Simões; Paula Soares; João Vinagre
Journal:  Genes (Basel)       Date:  2018-05-03       Impact factor: 4.096

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.